Park occupier, Isogenica Ltd, a leader in the design and construction of innovative and highly diverse synthetic antibody libraries, today announced that Harpoon Therapeutics, a preclinical stage biotechnology company specialising in the development of multiple T-cell recruiting platforms for the treatment of cancer and other immunologic disorders, is renewing the licence and option agreement originally signed with Isogenica in June 2016.
Under the terms of the original agreement, Isogenica has granted Harpoon licences to its family of llamdA™ VHH single-domain antibody libraries for the discovery, development and commercialisation of therapeutic products derived from these libraries. Isogenica is entitled to an upfront and annual licence payments. If antibodies are advanced into development, Isogenica is entitled to further commercial upfront payments, licence fees and milestones payments.
Adam Collier, Isogenica’s Director of Commercial Development commented: “We are delighted that Harpoon, one of our earliest VHH library licensees, has made the decision to renew this licence and option agreement. Isogenica sees this as further validation of the library in a truly operational setting. With our unique synthetic antibody libraries and leading biopharmaceutical discovery technologies, Isogenica is uniquely positioned to create significant value and opportunities for our partners”.
Isogenica is a synthetic biology company focusing on the design and build of diverse antibody libraries for use in biopharmaceuticals. Find out more here.